Benchmarking Biomarkers In Clinical Trials
Where does pharma stand in its use of biomarkers to assess clinical trial efficacy and safety or to preselect patients? A new report by Informa establishes a benchmark for measuring biomarker adoption and impact.
You may also be interested in...
Nearly half of all late-stage cancer trials that started in 2015 had an antibody component, and 2016 brings the first full survival data from pivotal multi-checkpoint antibody trials. We document the immuno-oncology surge in data.
In Vivo's editors pick January's most significant deals, including Roche's acquisition of Flatiron and Moderna's latest big private fundraising. (Free article.)
In Vivo's editors pick January's most significant deals, including an alliance of players new to health care and Celgene's big buys. (Free article.)